Read as much as you want on BostonGlobe.com, anywhere and anytime, for just 99¢.

Map Pharmaceuticals

Continue reading below

Regulators did not reject Map’s inhalable migraine drug because of safety or effectiveness and don’t want new studies, CEO Tim Nelson said - it was about manufacturing issues. Levadex is an inhaled form of a 60-year-old migraine drug that’s injected. Map, of Mountain View, Calif., seeks approval for its use in patients with 15 or fewer migraines a month; it would be Map’s first marketed product. The shares’ drop was a “knee-jerk reaction,’’ said Liana Moussatos, at Wedbush Securities. “It sounds like there are just manufacturing issues, no clinical safety issues.’’

Loading comments...
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com